VERAXA Biotech (NASDAQ: VRXA), a Switzerland-based biotechnology company with a significant financial and regulatory presence in the United States, is expanding its use of human-relevant testing methods across its oncology research programs. The company announced on October 7, 2026, that it is implementing New Approach Methodologies (NAMs), a collection of non-animal research techniques that includes cell-based assays and computational modeling, to generate more clinically informative preclinical data while reducing the number of animals required for drug development.
The strategy supports the development of VERAXA’s BiTAC(R) T-cell engagers, BiTAC-based antibody-drug conjugates, and bispecific antibody-drug conjugates for the treatment of cancer. According to the company, new three-dimensional spheroid data reinforce the ability of its models to assess the dual-target specificity of its lead T-cell engager candidates. In one ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, only about 10 mice were required, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company reports that its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity.
This shift toward NAMs matters for investors and the broader biopharma industry because it could lead to more predictive preclinical data, potentially improving the odds of clinical success for cancer therapies while addressing growing regulatory and ethical pressure to reduce animal testing. The FDA has been encouraging the adoption of NAMs, and VERAXA’s move aligns it with that regulatory direction. For patients, more human-relevant testing may translate into therapies that are better optimized for human biology before entering clinical trials.
VERAXA’s announcement was distributed through MissionIR, a communications platform that is part of the Dynamic Brand Portfolio at IBN. MissionIR provides services including wire distribution via InvestorWire, editorial syndication to 5,000+ outlets, and social media distribution. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
As drug developers face increasing scrutiny over the translatability of animal studies, VERAXA’s expanded use of human-relevant models could set an example for other oncology-focused companies. The approach may also help streamline research and development timelines and costs by reducing reliance on large in vivo studies. However, the company has not disclosed specific financial terms or timelines for the broader rollout of NAMs across its pipeline.
